Selecta Biosciences, which is developing nanoparticles that modulate the immune system to enhance biologics, raised $70 million by offering 5 million shares at $14. It had originally planned to raise $64 million by offering 4.25 million shares at $14 to $16. Selecta Biosciences plans to list on the Nasdaq under the symbol SELB. UBS Investment Bank and Stifel acted as lead managers on the deal.
